{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:15:24Z","timestamp":1788419724087,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate the value of a novel composite index, the ALP score (calculated as the product of lymphocyte count and serum albumin), in predicting the risk of early progression to chemotherapy combined with immune checkpoint inhibitors (ICIs) in patients with driver mutation-negative advanced non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data from 433 patients with advanced NSCLC who received first-line chemoimmunotherapy were retrospectively collected. Independent risk factors for early progression (defined as progressive disease, PD) were identified using univariate and multivariate logistic regression analyses. The predictive power of the ALP score for PD was evaluated, and its nonlinear relationship with risk was explored using restricted cubic splines (RCS). Ten machine learning models and the SHAP interpretability technique were further employed to validate the importance of the ALP score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Multivariate analysis identified the absence of liver metastasis and the absence of bone metastasis as independent protective factors against early progression, whereas lower lymphocyte count, lower albumin level, and lower Body Mass Index were identified as independent risk factors. The ALP score predicted PD with an AUC of 0.643, outperforming its individual components. Critically, multivariable analyses confirmed the ALP score as an independent predictor for both endpoints: patients in the highest score tertile had significantly lower risks of early progression (OR\u00a0=\u00a00.33, P\u00a0=\u00a00.001) and disease progression or death (HR\u00a0=\u00a00.65, P\u00a0=\u00a00.002) compared to the lowest tertile. RCS analysis revealed a significant nonlinear inverse relationship between the ALP score and PD risk (P&amp;lt;0.05). Machine learning models (best model AUC\u00a0=\u00a00.655) and SHAP analysis consistently confirmed the ALP score as a key predictive feature for disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The ALP score, a composite index derived from routine laboratory parameters, serves as an accessible and practical prognostic marker associated with early progression risk and progression-free survival in patients with advanced NSCLC. Reflecting baseline systemic immune and nutritional readiness, it offers a practical and low-cost tool for clinical risk stratification in patients receiving chemo-immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1889854","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:40:37Z","timestamp":1788417637000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The ALP score: a novel composite index for prognostic risk stratification to chemo-immunotherapy in advanced non-small cell lung cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Yize","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Yiyang Central Hospital","place":["Yiyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ultrasound in Medicine, Yiyang Central Hospital","place":["Yiyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yiyang Central Hospital","place":["Yiyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yiyang Central Hospital","place":["Yiyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yan","sequence":"additional","affiliation":[{"name":"Early Clinical Trial Center, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yiyang Central Hospital","place":["Yiyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianxi","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yiyang Central Hospital","place":["Yiyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2025.08.011","article-title":"Immune checkpoint inhibitor without pemetrexed for first-line maintenance therapy in advanced lung adenocarcinoma: A real-world retrospective study","volume":"26","author":"Gao","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1186\/s12967-025-07408-z","article-title":"Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer","volume":"23","author":"Dai","year":"2025","journal-title":"J Transl Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s00262-025-04181-2","article-title":"Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer","volume":"74","author":"Chen","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143294","article-title":"Primary and acquired resistance against immune check inhibitors in non-small cell lung cancer","volume":"14","author":"Sun","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127071","article-title":"Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy - are we making headway","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004863","article-title":"Addressing CPI resistance in NSCLC: Targeting TAM receptors to modulate the tumor microenvironment and future prospects","volume":"10","author":"Peters","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163846","article-title":"Circulating low density neutrophils are associated with resistance to first line anti-PD1\/PDL1 immunotherapy in non-small cell lung cancer","volume":"14","author":"Arasanz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1186\/s12885-025-15173-x","article-title":"Peripheral lymphocyte count as a prognostic marker in cervical cancer patients treated with immune checkpoint inhibitors: A retrospective study","volume":"25","author":"Dofutsu","year":"2025","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.13220","article-title":"Cytotoxic T lymphocyte density and PD-L1 expression predict the response to anti-PD1 therapy in recurrent oral squamous cell carcinoma","volume":"69","author":"Yamashita","year":"2025","journal-title":"Microbiol Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1286583","article-title":"Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Nutr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.18502\/ijaai.v24i2.18141","article-title":"Predictive value of the lung immune prognostic index for immune checkpoint inhibitor therapy outcomes in non-small cell lung cancer: A systematic review and meta-analysis","volume":"24","author":"Lu","year":"2025","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2198","article-title":"Mutational landscape of recurrent\/metastatic head and neck squamous cell carcinoma and association with immune checkpoint inhibitor outcomes","volume":"31","author":"McCoon","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41598-021-04630-9","article-title":"Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6645","article-title":"Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy","volume":"12","author":"Goldschmidt","year":"2023","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048966","article-title":"Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"51","author":"Ku","year":"2021","journal-title":"Eur J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.12.010","article-title":"Serum albumin: Early prognostic marker of benefit for immune checkpoint inhibitor monotherapy but not chemoimmunotherapy","volume":"23","author":"Guo","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100254","article-title":"Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer","volume":"6","author":"Mountzios","year":"2021","journal-title":"ESMO Open"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889854\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:40:37Z","timestamp":1788417637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889854\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2026.1889854"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1889854","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1889854"}}